REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $27.70.

A number of brokerages have recently commented on RGNX. Morgan Stanley decreased their price target on shares of REGENXBIO from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday. Barclays started coverage on REGENXBIO in a research report on Tuesday, January 27th. They set an “overweight” rating and a $37.00 price target on the stock. Robert W. Baird set a $27.00 price objective on REGENXBIO in a report on Tuesday, February 10th. Chardan Capital reduced their price objective on REGENXBIO from $52.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Finally, Royal Bank Of Canada raised their price objective on REGENXBIO from $17.00 to $19.00 and gave the company an “outperform” rating in a report on Friday, November 7th.

REGENXBIO Trading Down 0.8%

Shares of RGNX opened at $8.65 on Friday. REGENXBIO has a 12-month low of $5.03 and a 12-month high of $16.19. The company has a market cap of $437.86 million, a PE ratio of -2.30 and a beta of 1.08. The stock has a 50-day moving average price of $11.47 and a 200-day moving average price of $11.39.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.31). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The company had revenue of $30.34 million during the quarter. As a group, analysts predict that REGENXBIO will post -4.84 earnings per share for the current year.

Institutional Investors Weigh In On REGENXBIO

A number of institutional investors have recently made changes to their positions in RGNX. State of Alaska Department of Revenue bought a new position in shares of REGENXBIO during the 3rd quarter valued at $25,000. Aquatic Capital Management LLC bought a new position in shares of REGENXBIO during the third quarter valued at about $37,000. Jones Financial Companies Lllp increased its holdings in shares of REGENXBIO by 44.4% in the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after buying an additional 1,270 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in shares of REGENXBIO by 754.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after buying an additional 5,000 shares during the period. Finally, Captrust Financial Advisors bought a new stake in shares of REGENXBIO in the 2nd quarter valued at about $85,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO News Roundup

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Pipeline catalysts approaching — management reported that RGX‑202 (Duchenne) has topline pivotal results expected early Q2 2026, RGX‑314 (sura‑vec / wet AMD) has topline pivotal data expected Q4 2026, a pivotal Phase IIb/III diabetic retinopathy trial has started dosing, and the company plans to engage the FDA on a path forward for RGX‑121. These upcoming readouts are potential upside catalysts if data are positive. REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
• Neutral Sentiment: Company provided earnings materials and management commentary — full Q4 2025 earnings call transcripts and highlights are available for investors to review for program timelines, cash guidance and cost trajectory. Use these to reassess runway and probability of late‑stage success. REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed expectations — REGENXBIO reported EPS of ($1.30) vs. consensus (~($0.99)) and revenue of $30.34M, highlighting continued losses and pressure on near‑term financials. The miss increases scrutiny on execution and funding assumptions ahead of costly pivotal readouts. Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Multiple law firms are soliciting lead‑plaintiff investors and reminding shareholders of an April 14, 2026 deadline in a securities class action covering Feb 9, 2022–Jan 27, 2026. The flurry of Rosen, Schall, Faruqi, Pomerantz and others’ notices signals heightened litigation risk and potential future liabilities or settlements that could pressure the stock. ROSEN, A LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGNX
• Negative Sentiment: Sector‑wide regulatory caution — recent FDA reversals and tougher review posture for experimental drugs are spooking investors in gene‑therapy and biotech names; this increases binary outcome risk ahead of REGENXBIO’s pivotal readouts. FDA reversals leave investors worrying about the fates of other experimental drugs

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.